NewsHealth / June 2, 2020

Lilly Begins World's First Study Of Potential COVID-19 Antibody Treatment in Humans

Lilly Begins World's First Study Of Potential COVID-19 Antibody Treatment in Humans

Indianapolis-based Eli Lilly and Company announced Monday that patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.

According to a news release, this investigational medicine -- referred to as LY-CoV555 -- is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.

Lilly scientists developed the antibody after AbCellera and the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) identified it from a blood sample taken from one of the first U.S. patients who recovered from COVID-19. Lilly says it's the first potential new medicine specifically designed to attack the virus that causes COVID-19.

The first patients in the study were dosed at major medical centers in the U.S., including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles. 

If Phase 1 results show the antibody can be safely administered, Lilly says it expects to move into the next phase of testing, studying the treatment in non-hospitalized COVID-19 patients. The company also plans to study the drug in a preventative setting, focusing on vulnerable patient populations who historically are not optimal candidates for vaccines.

Lilly says it is researching multiple approaches to treating COVID-19.


At WFYI, our goal is to cover stories that matter to you. Our reporting is rooted in facts. It considers all perspectives and is available to everyone. We don't have paywalls, but we do need support. So if unbiased, trusted journalism is important to you, please join us. Donate now.



Related News

Anthem To Pay Nearly $40M Settlement Over 2015 Cyberattack
Updates On COVID-19 In Indiana: 965 Cases, 20 Deaths Added To State's Totals
Statewide COVID-19 Testing Set To Begin Third Phase, Include Children